Molecular analysis of PTEN and MXI1 in primary bladder carcinoma
โ Scribed by David S. Wang; Kimberly Rieger-Christ; Jerilyn M. Latini; Ali Moinzadeh; John Stoffel; John A. Pezza; Kulvinder Saini; John A. Libertino; Ian C. Summerhayes
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- French
- Weight
- 139 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A tumor suppressor gene on chromosome sub-band 10q23.3, PTEN, is frequently mutated or deleted in a variety of human cancers. Germline mutations in PTEN, that encodes a dual-specificity phosphatase, have been implicated in two hamartomatumor syndromes that exhibit some clinical overlap, Cowden syndr
The PTEN gene, recently identified on chromosome 10q23, has been proposed to be a candidate tumor suppressor gene inactivated in multiple cancers including glial tumors. We investigated 47 glioblastomas (GBM), 14 anaplastic astrocytomas (AA), 6 non-pilocytic low-grade astrocytomas (LGA), 21 low-grad
## Loss of heterozygosity (LOH ) at chromosome band 10q23 occurs frequently in a wide variety of human tumors. A recently identified candidate tumor suppressor gene, PTEN located on 10q23, is mutated in multiple advanced cancers. To explore whether PTEN is associated with human squamous cell carci
## Abstract ## BACKGROUND The urinary concentration of soluble cytokeratin 19 fragments, measured by the CYFRA 21โ1 assay, may be used for the noninvasive, early detection of bladder carcinoma. ## METHODS This prospective study examined urine samples from 325 patients. The authors included 152 p